索引超出了数组界限。
[ 1 ] Sambandam KK. Effective use of loop diuretics in heart failure exacerbation: a nephrologist's view[J]. Am J Med Sci, 2014, 347(2):139-145.
[ 2 ] Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans[J]. Lancet, 2008, 371(9624):1624-1632.
[ 3 ] Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia[J]. N Engl J Med, 2006, 355(20):2099-2112.
[ 4 ] 魏宇淼, 陈芬, 杨仕俊, 等. 托伐普坦在重症心力衰竭容量控制及心衰症状改善中的疗效观察[J]. 中国医院药学杂志, 2015, 35(13):1228-1230.
[ 5 ] 吴章民, 袁方. 托伐普坦治疗左心瓣膜置换术后三尖瓣关闭不全伴右心衰的临床研究[J]. 国际心血管病杂志, 2018, 45(2):105-108.
[ 6 ] Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the Everest Clinical Status Trials[J]. JAMA, 2007, 297(12):1332-1343.
[ 7 ] Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial[J]. Circulation, 2003, 107(21):2690-2696.
[ 8 ] Konstam MA, Gheorghiade M, Burnett J, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure—the Everest outcome trial[J]. JAMA, 2007, 297(12):1319-1331.
[ 9 ] Udelson JE, Mcgrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction[J]. J Am Coll Cardiol, 2007, 49(22):2151-2159.
[10] 刘琛. 托伐普坦可导致血钠水平快速升高和严重神经症状[J]. 药物不良反应杂志, 2012, 14(2):76.
[11] Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease[J]. N Engl J Med, 2012, 367(25):2407-2418.